Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding cannabinoids to opioids doesn’t improve cancer pain control

Publish date:: January 22, 2020

Key clinical point: Cannabinoids added to opioids did not reduce mean patient-reported pain scores.

Major finding: There was no significant difference in the mean difference in pain intensity between cannabinoids and placebo.

Study details: Systematic review and meta-analysis of five randomized controlled trials with 1,442 participants.

Disclosures: The authors did not report a funding source. No conflicts of interest were reported.

Citation:

Boland EG et al. BMJ Supportive & Palliative Care 2020 Jan 20. doi: 10.1136/bmjspcare-2019-002032.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Opioid Resource Center

Adding cannabinoids to opioids doesn’t improve cancer pain control,

Survey: Cancer-Related Pain, Opioid Use Up Since 2018,

Cancer pain management inadequate in opioid-saturated areas,

Opioid Retail Prescriptions Declined 33% Over 5 Years,

Sickle cell pain: Opioids appear safe for inpatients, Akinboro OA et al. ASH 2018, Abstract 315

All Specialties